Back

Close - PCSK9 inhibitors: the next chapter in CVD prevention.

27 August 2017 (13:40 - 13:45)
Organised by:
Congress Presentation Part of: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in cardiovascular disease prevention Atherosclerosis Open Access ESC Congress 2017

About the speaker

Photo
Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)

4 More presentations in this session

Presentation thumbnail
Introduction - PCSK9 inhibitors: the next chapter in CVD prevention.
Video
Presentation thumbnail
CVD prevention and event reduction.
Professor M. Sabatine (Boston, US)
Presentation thumbnail
Future perspectives in lipid lowering and CVD prevention.
Professor P. Sever (London, GB)
Presentation thumbnail
Panel discussion - PCSK9 inhibitors: the next chapter in CVD prevention.
Professor J. Chapman (Paris, FR)

Access the full session

Session thumbnail
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in cardiovascular disease prevention

The Event

Event poster

ESC Congress 2017

27 August 2017 13:40 CET
You may be interested in
thumbnail
Congress Presentation
Early PCSK9 inhibitor subscription during episode of acute myocardial infarction (EPISODE-AMI) study
1 September 2025
thumbnail
Congress Presentation
How to manage lipid risk pharmacologically – new approaches
13 April 2023
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials
30 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources